ValiRx PLC
LSE:VAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
IWS Group Holdings Ltd
HKEX:6663
|
HK |
|
E
|
eToro Group Ltd
NASDAQ:ETOR
|
IL |
|
North Media A/S
CSE:NORTHM
|
DK |
|
FormPipe Software AB
STO:FPIP
|
SE |
|
Eloxx Pharmaceuticals Inc
OTC:ELOX
|
US |
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
|
ValiRx PLC
LSE:VAL
|
2.3m GBP |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
384.5B USD |
Loading...
|
|
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
361.6B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.6B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67.9B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -195 650% |
| 30th Percentile | 0% |
| Median | 0.1% |
| 70th Percentile | 0.2% |
| Max | 4 630.7% |
Other Profitability Ratios
ValiRx PLC
Glance View
ValiRx Plc is a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards commercialization and partnering. The company is headquartered in Nuneaton, Warwickshire and currently employs 10 full-time employees. The company went IPO on 2000-02-28. The firm is engaged in the development of oncology therapeutics and companion diagnostics. The company focuses on the development of treatments in cancer and women’s health. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. Its VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer. Its VAL301 for the treatment of women with endometriosis. Its VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. Its BC201 is a combination of the peptide ingredient of VAL201 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. The company operates through divisional companies, including ValiPharma and ValiSeek.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for ValiRx PLC is -4 051.4%, which is above its 3-year median of -13 816.6%.
Over the last 2 years, ValiRx PLC’s Operating Margin has increased from -23 942.7% to -4 051.4%. During this period, it reached a low of -23 942.7% on Dec 31, 2023 and a high of -4 051.4% on Jul 30, 2025.
